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Naïve T cells activated by antigen-presenting cells (APC) can be
differentiated into at least four major types of T-helper (TH) cells:
TH1, TH2, TH17 and inducible regulatory T cells (iTreg) based on
their unique cytokine production profiles and characteristic
functions.
1 TH1 produce interferon-c (IFNc) and are important
for protective immune responses to intracellular viral, bacterial
and parasitic infection. TH2 cells produce interleukin-4 (IL-4),
IL-5, IL-23 and are critical for controlling extracellular parasites
such as helminthes. TH17 cells are responsible for expelling
extracellular bacteria and fungi through secretion of IL-17a,
IL-17f and IL-22.
2 These cells however are perhaps better known
for their propensity to drive autoimmune responses. Tregs
including naturally occurring regulatory T cells (nTreg) play
important roles in the suppressive control of both innate and
adaptive immunity in vivo.
3,4
Introduction
In this review, we discuss a number of recent studies suggesting
crucial roles for metabolic sensor molecules in the regulation of
the balance between these opposing, yet developmentally linked
T-cell subpopulations. Understanding the factors impacting the
generation of these cells is of considerable importance. An
imbalance between TH17 and Treg cell function may result in
some inflammation mediated diseases (such as IBD), autoimmune
diseases and cancer.
The Mammalian Target of Rapamycin
(mTOR)/Hypoxia-Inducible Factor 1 (HIF-1) Axis,
as an Environmental Sensor, Plays an Important Role
in T-Cell Fate Determination
Rapamycin was originally identified as an antifungal compound
derived from Streptomyces hygroscopicus, found in soil samples
collected from Easter Island. A potent immunosuppressive drug
with a target, which was identified a decade ago as FKBP-
rapamycin-associated protein (FRAP, mTOR), a serine-threonine
protein kinase. mTOR integrates environmental cues as a means
of regulating cellular size, growth, proliferation, survival and
metabolism. Its activity can be regulated by diverse stimuli such as
amino acid availability, oxygen tension, energy status and growth
factors.
5 The role of mTOR in cancer and T cell biology has
been comprehensively reviewed recently.
6 Work from Powell and
colleagues found that mTOR plays a significant role in the
generation of effector T cells. They discovered that in the absence
of mTOR, naïve CD4
+ T cells differentiate preferentially into
Foxp3
+ Tregs. Mechanistically, the inability to become effector
cells in mTOR null T-cell mice was associated with a failure to
upregulate appropriate T helper subset-specific transcription
factors (such as Tbet for TH1 cells). These mice also displayed
decreased STAT activation in response to various skewing
cytokines. Along these lines, it has been shown that STAT3-
deficient T cell are incapable of becoming TH17 cells. In this way,
mTOR, a central regulator of cellular metabolism and protein
translation, integrates various extracellular and intracellular signals
to promote effector but not regulatory T-cell differentiation.
7
Recently, another study identified mTOR, and particularly
elements downstream in its signaling as being crucial to T effector
cell differentiation.
8 However, they found this signaling axis to
be indispensible for one particular lineage. Combining phar-
macological and genetic approaches, Shi et al. demonstrated
elegantly that the basic metabolic machinery in different subsets
of T cells is actively regulated and involved in T-cell fate deter-
mination. These authors report that TH17 and Treg cells have
marked differences in their glycolytic activity and expression of
glycolytic enzymes. They also found that glycolysis serves as a
key metabolic checkpoint to direct the cell fate determination
between these lineages. Specifically, the glucose analog 2-
deoxyglucose (2-DG), a prototypical inhibitor of the glycolytic
pathway, dampened the development of naïve precursors into
TH17 cells while promoting Treg cell generation. Additionally,
deficiency in the transcription factor hypoxia-inducible factor 1a
(HIF1a)—which is downstream of mTOR signaling—in T cells
diminished expression of the glycolytic molecules and skewed
the dichotomy between the TH17 and Treg lineages in agreement
with studies from our own group that will be discussed below.
These findings demonstrate that HIF1a-induced metabolic
reprogramming orchestrates lineage differentiation of T cells. In
the following sections we will discuss more studies concerning
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this metabolically important regulator that expand upon its role
in T-cell differentiation and disease.
Hypoxia Inducible Factor (HIF)-1, a Major Oxygen
Sensor and Metabolic Regulatory Transcription
Factor, is Involved in the Regulation of the Balance
between Treg and TH17 Cell Differentiation
HIF-1 is a heterodimeric transcription factor consisting of a
highly regulated oxygen sensitive HIF-1a subunit and a con-
stitutively present β subunit (termed HIF-1β or ARNT, which
interestingly is also the non-ligand binding subunit of the AHR).
HIF-1a was originally discovered by Semenza and colleagues as a
hypoxia responsive factor activating erythropoietin transcription.
Since its discovery, the expanded role of HIF-1 as a central
regulator of metabolic programs has been delineated. As a
sequence-specific DNA-binding transcription factor for 100–200
genes that regulate adaptation to hypoxia, HIF-1 has attracted
considerable attention in fields ranging from ischemia to cancer.
9
As part of its role in the hypoxia response, HIF-1 also regulates
multiple metabolic genes including those involved in glucose
transport and glycolysis.
Sensing of oxygen tension occurs at the level of HIF-1a pro-
tein stability. Under normoxic conditions HIF-1a degradation
is initiated through hydroxylation by the Phd family of
2-oxoglutarate- and iron-dependent dioxygenases. Further meta-
bolic regulation of Phd activity comes from the capacity of
various species such as ROS and succinate to compete with 2-
oxoglutarate for Phd binding. Elevated reactive oxygen species
(ROS) can also affect HIF-1 levels via inactivation of Phds
through oxidation of the ferrous ion at the active site. Hydro-
xylation of HIF-1a at a specific proline (402 in murine HIF-1a)
by Phd recruits the Von Hippel Lindau (VHL) and an E3 Ub
ligase (along with the associated catalytic complex containing
elongin B/C, RBX1 and cullin2) and ubiquitinated HIF-1a is
degraded by the proteosome. Oxygen is not the only regulator
of HIF-1 levels. It is transcriptionally activated by a number
of signaling pathways important in immune responses, notably
those of NFkB and STAT3. Not surprisingly, the HIF-1 pathway
interacts with other pathways that regulate metabolism such as
mTOR signaling. For example, mTOR regulates translation of
HIF-1a mRNA whereas certain HIF-1 activated genes, such as
BNIP3 and REDD1, encode proteins that feedback inhibits
mTOR activity (Fig.1).
Figure1. HIF-1’s regulation and its role in driving the TH17 genetic program. In CD4
+ T cells, under normoxic conditions, HIF-1 is generated and promptly
marked for proteasomal degradation. This is accomplished by proline hydroxylation at a specific proline residue by the PHD dioxygenases—an event
that recruits the Von Hippel Lindau (VHL) and an E3 ligase that polyubiquitinates the HIF-1 molecule. Under hypoxia, the degradation machinery is
inactive and HIF-1 protein accumulates. Under normoxia, however, HIF-1 expression can also be dramatically upregulated by a number of stimuli
including TCR signaling and proinflammatory cytokines (such as IL-6 which activates the STAT3 signaling cascade). This expanded pool of HIF-1 protein
activates expression of the TH17-associated transcription factor, RORct which in turn complexes with HIF-1 and other factors to spur on transcription at
the IL-17 gene as well as other TH17 loci. Additionally, HIF-1 binds to Foxp3 and mediates its co-degradation via the proteasome favoring the generation
of IL-17 producing T cells over that of iTreg.
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How HIF-1 and hypoxia impact the immune system is no
trivial matter as oxygen levels at sites of infection, inflammation
or injury can approach or reach hypoxic levels.
10 Tumors are
notorious for their hypoxic or even anoxic regions. Given the
likelihood of immune cells encountering low oxygen levels as they
execute their various functions in the periphery, how hypoxia
and elements of the hypoxic response (such as HIF-1) impact
immune cell function is a highly relevant topic. As interest in
understanding the complex metabolic regulation of immune
responses grows, study of the role of hypoxia-sensing and the
HIF-1 pathway in the innate immune response has intensified.
11
The role of HIF-1 in adaptive immunity, however has only
recently begun to be elucidated. Recently, we and others reported
that HIF-1 during oxygen scarcity in fact regulates the TH17/
Treg balance in a multifaceted manner.
8,12 Specifically, we have
discovered that HIF-1 promotes TH17 differentiation by directly
inducing RORct transcription and subsequently collaborating
with RORct to regulate downstream TH17 genes. In addition,
HIF-1 inhibits Treg differentiation through an active process that
targets Foxp3 protein for degradation. Our study sheds light
on how the balance between these highly plastic differentiation
programs can be subject to metabolic regulation and suggests
new strategies to manipulate these cell lineage decisions in order
to treat diseases associated with a TH17/Treg imbalance. As pre-
viously mentioned, Shi et al. have found that HIF-1 is necessary
for optimal TH17 differention in vitro and in vivo. Interestingly,
this study, also done in the murine system attributed HIF-1’sr o l e
in TH17 generation to be that of an inducer of glycolytic genes
needed for TH17 lineage commitment suggesting another possible
mechanism for HIF-1 in the process besides or in addition to
its direct role in regulating TH17-associated loci. An additional
dimension of HIF-1’s involvement in TH17 biology was recently
suggested by Kryczek et al. Using a HIF-1 inhibitor and shRNA
mediated knockdown, they found that HIF-1 was necessary for
preventing apoptosis of human TH17 cells by inducing several
survival promoting genes. The results of this study suggest that
HIF-1 may allow for the persistence of TH17 cells
13
HIF-1 as a Therapeutic Target in Inflammation
Diseases, Autoimmune Diseases and Cancer
The role of HIF-1 as a positive regulator of the TH17 response has
been established by the work of several groups including our
own.
8,12,13 Studies using cell lineage specific HIF-1 deficient
mice or T cells from these animals have been central to these
discoveries. Genetic ablation of HIF-1 function, however does
not speak to the suitability of HIF-1 modulation as a therapy to
counter undesirable TH17 responses. Work concerning HIF-1’s
role in cancer biology, however does suggest that the downstream
effects of HIF-1 signaling can be modulated with inhibitor
compounds.
HIF-1 is known to play a major role regulating several aspects
of cancer cell biology. HIF-1 targets include genes crucial for cell
immortalization, vascularization and glyolytic metabolism. Since
hypoxia is a common element of the tumor microenvironment,
and pronounced HIF-1 expression during cancer has been linked
to poorer prognoses and patient survival, it is not surprising that
efforts to identify inhibitors of HIF-1 function have been taken
up in earnest by cancer biologists. Indeed, a number of inhibitors
with diverse mechanisms of action have been identified and tested
in vitro and in vivo for their effectiveness at counteracting HIF-1
mediated tumor processes.
14 Among the compounds shown to
have potent HIF-1 antagonizing properties is a drug known as,
digoxin. This cardiac glycoside was identified by the Semenza
group to be a potent inhibitor of HIF-1 function.
15 Recently, the
Littman group found that this compound and its derivatives
were also potent antagonists of TH17 responses.
16 Specifically,
treatment of mice with digoxin inhibited the generation of a
TH17 response in mice subjected to EAE. As a result, these mice
were protected from the immune mediated neuropathology seen
in this model of human MS. While the authors attribute the
action of digoxin to inhibition of RORct, a key regulator of TH17
development, it is reasonable to suspect that the drug may have
impacted HIF-1 levels, as has been previously reported. It is also
noteworthy that the Treg/TH17 imbalance seen in digoxin treated
cells mirrors that seen upon genetic ablation of HIF-1.
12 Other
characterized HIF-1 inhibitors include a range of agents with
distinct modes of action.
14 Unpublished findings from our group
corroborate those of the aforementioned drug study and suggest
that using other HIF-1 inhibitors can also suppress in vivo TH17
mediated pathology as well (FP and DP unpublished results).
These findings strongly suggest that such molecules, due to their
ability to dramatically reduce the severity of TH17 responses, are a
pool of drugs with a great deal of potential as treatments for
inappropriate or excessive T-cell responses of this kind.
While the effectiveness of HIF-1 inhibition as a therapy for
autoimmune diseases has been demonstrated (at least in animal
models), it remains to be determined which consequence of
HIF-1 functional ablation is chiefly responsible for this protection
from autoimmune disease; the reduced TH17 response or the
enhanced presence of Treg cells. The findings of Korn et al. that
antigen specific Tregs accumulating in the CNS are insufficient
to control EAE suggest that reducing the development of a
robust TH17 response in the first place may be more beneficial
in EAE.
17 Indeed, further study may shed light on this question.
The treatment of other autoimmune diseases having a strong
IL-17 component may benefit from including HIF-1 inhibition
in the treatment arsenal. It is reasonable to expect that inflam-
matory bowel disease (IBD) may also be ameliorated upon HIF-1
inhibition since the balance between TH17 and Tregs has been
shown to impact disease severity. Of course, future work is will be
needed to validate this notion. While it seems likely that HIF-1
inhibition is well suited as an anti-autoimmune intervention,
the setting of cancer, however, presents a more complicated
scenario in regards to the suitability of HIF-1 targeting as a
treatment method.
In the marshalling of an effective anti-tumor response, the
proinflammatory, TH1-associated cytokines IFNc and IL-12 play
an undeniable role in promoting the killing of cancer cells. CD8
+
cytotoxic T lymphocytes also are important for the destruction
of tumor cells. On the other hand, the action of Tregs in the
anti-tumor response has been shown repeatedly to be negatively
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associated with the effectiveness of the response and overall disease
outcome.
18 Tregs are known to accumulate in tumor tissues and
depleting them or inhibiting their suppressive function increases
the effectiveness of certain cancer vaccines. For this reason, the
sabotaging of Tregs has become an aim of many developing
immunotherapy approaches.
The impact of TH17 cells in the tumor setting is less cut-and-
dry. While they have been observed to accumulate in many cancer
patients often along side Tregs, their contributions to either
tumor progression or tumor eradication is the subject of some
debate. TH17 cells have been reported by some to be efficient
participants in the anti-tumor response.
19 Furthermore, in a
recent study, adoptive transfer TH17 cells slowed the growth of
established ovarian tumors in immunodeficient mice. Co-transfer
of these cells with tumor antigen specific CD8
+ T cells had an
even greater effect on tumor growth.
13 Not only does this study
suggest that, at least after tumor initiation, TH17 cells have anti-
tumor capacities, it also raises the possibility that cooperation
with other effector T cells may be key for this function. On the
other hand, mounting numbers of studies suggest that IL-17 and
the cells producing it promote tumor growth and progression.
In particular, TH17 and IL-17 producing T cells have been
linked to poorer prognoses in cancer patients or numerous types.
20
IL-17 more clearly contributes to the progression of inflammation
associated tumors. In colorectal cancer, IL-17 producing Foxp3
+
are thought to be important instigators of disease—suggesting
that Treg cells may play a more active role in tumor progression,
beyond dampening a desirable anti-tumor response. Moreover it
was found that exposure to hypoxia could bring about IL-17
expression by Treg cells showing that this condition, which almost
certainly involves upregulation of HIF-1, can also drive Treg
cells, under the right conditions, to become active participants
in an IL-17 driven response. Another strong link between TH17
cells and tumor progression was seen in a model of colon cancer
induced by a wide spread human commensal organism. Experi-
mental colonization of mice predisposed to intestinal tumors with
an enterotoxigenic strain of Bacteriodes fragilis results in the
aggressive development of large bowel tumors.
21 In these studies,
deletion of STAT3 in the CD4
+ compartment or anti-IL-17
antibody treatment greatly reduced cancer severity providing
another example of IL-17’s tumor promoting capacity.
The underlying mechanisms by which IL-17 and the cells that
produce it influence tumor formation and progression remain to
be completely defined. However, recently, several studies have
linked TH17 cells or the cytokines they are known to produce to
the promotion of angiogenesis- a process both characteristic and
necessary for tumor development. In gastric cancers, vasculariza-
tion of tumors is positively correlated with the levels of IL-17 and
TH17 associated cytokine mRNA in the tumor tissue.
22 IL-17
producing cells which are enriched in colorectal cancer (CRC)
tumor tissues are associated with poor prognosis at least in part
due to the induction of the infamous pro-angiogenic factor,
VEGF in the cancer cells. Indeed, HIF-1 within the cancer cell
itself has been clearly shown to be important for regulating genes
important for angiogenesis.
9 All the same, the possibility that
IL-17 producing T cells influence their intra-tumor neighbors
should be considered. Interestingly, Hot and Miossec have
reported that the TH17-associated cytokines can induce the
expression of genes linked to the hypoxic response
23 suggesting
that TH17 responses may be subject to positive feed back loop
regulation. Therefore, one wonders if tumor infiltrating IL-17
+
T cells might perpetuate a pro-angiogenic chain reaction through
interaction with other cells of the tumor microenvironment. In
addition to an apparent pro-angiogenic role of TH17 associated
cytokines, some reports suggest that they play a role in cancer
spread as well. Recently, Li et al. reported that IL-17A can
promote hepatocellular carcinoma metastasis through the regu-
lation of metalloprotease expression.
24 In addition to promoting
cytokines with tumor promoting capacities, HIF-1’s regulation
of glycolysis-associated genes in cancer cells is considered a major
contribution to the progression of tumors. Specifically, HIF is
important for the establishment of the Warburg effect. In this
metabolic shift from aerobic respiration, the machinery of
glycolysis is upregulated in cancer cells, giving them a metabolic
advantage for surviving and thriving in the oxygen poor micro-
environment of the tumor. It is likely that HIF-1 inhibitors will
rob the tumor cells of needed vascularization, a chance to spread
and the metabolic edge imparted by their glycolytic lifestyle.
In all it stands to reason that targeting HIF-1 in the tumor
microenvironment should prove an effective, multiple pronged
anti-cancer treatment strategy for a variety of cancers. Since as
mentioned above, certain effects of the TH17 response may
promote tumor development, growth and spread in some cancer
models and given HIF-1’s importance in the cancer cell itself,
well characterized HIF-1 inhibitors make tempting potential
therapeutic tools. Indeed pharmacological inhibition of HIF-1 in
tumor models has yielded promising, yet preliminary findings.
Specifically, Semenza and colleagues report that treatment of
mice with subcuteanous tumors with digoxin or acriflavine
(inhibitors of HIF-1 expression and function, respectively) limits
tumor growth.
15 In these and other studies, a major effect of
general HIF-1 inhibition was a reduction in neovascularization
(process of angiogenesis) and the switch to glycolytic metabolism.
Neither of these studies addressed how these inhibitors were
impacting the T cell response to the tumor and it remains to be
seen how much of the tumor growth suppressing effect of these
compounds is actually attributable to the presumed inhibition of
the TH17 response.
While chemical targeting HIF-1 appears to be a highly viable
anti-cancer strategy with multiple potential benefits, studies using
mice with HIF-1 deficient T cells sound a note of caution when
considering HIF-1 inhibition as monotherapy cancer treatment.
While HIF-1 inhibitors can interfere with the tumor-promoting
processes of angiogenesis and the favoring of glycolytic metabo-
lism, they may, as suggested by the previous work of our group
and others, also elevate the frequency of immune suppressive Treg
cells. These cells are known to stymie anti-tumor immune
response by promoting immune tolerance—a state permissive to
cancer persistence and progression. Nevertheless, it is still likely
that HIF-1 inhibition may yet prove particularly advantageous
in the treatment of cancer. It may be prudent or necessary to
evaluate the efficacy of HIF-1 inhibition as a cancer therapy
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in combination with other agents aimed at counteracting the
potential increases in suppressor cell generation such as the drugs
used to deplete Treg cells. Such a combinational approach, should
in theory, simultaneously neutralize two tumor-promoting T-cell
populations. Additionally, since some studies suggest that in the
latter stages of tumor development, TH17 cells have anti-tumor
effects, restricting the therapeutic window of HIF-1 inhibition
to early developing tumors may prove more effective as a
treatment strategy.
Concluding Remarks
While it is well appreciated that during T-helper cell differ-
entiation from naïve precursors, ultimate lineage choice is heavily
swayed by cytokine initiated signaling pathways, other sources
of environmental input that also influence T-cell lineage choice
are just being brought to light or still remain known. Recent
findings strongly suggest that metabolic cues can significantly
affect T-cell lineage choice. mTOR, a molecule involved in the
sensing numerous indicators of metabolic state, is important for
differentiation of naïve T cells into effector lineages.
7 Another
metabolic sensor heavily involved in steering T-cell differentiation
is HIF-1. This molecule, known to be an important regulator
of the cellular response to low oxygen level has been the topic
of several recent studies sharing a complimentary theme. Either
as a key inducer of the glycolysis dominated metabolic shift
necessary for TH17 development under the control of mTOR
signaling
8,12 (a regulator of and cooperative partner with the TH17
transcription factor RORct that interestingly sabotages the
protein level of the antagonistic Treg regulator, Foxp3) or as a
promoter of differentiated TH17 cell persistence HIF-1 is a major
regulator of the TH17 response. Additionally, reports of the TH17
suppressing properties of the HIF-1 inhibitor digoxin appear to
bolster this notion.
16 Future work should evaluate the potential
of HIF-1 inhibitors as autoimmune disease remedies and (with
concurrent management of Treg levels) anti-cancer agents. For the
latter, however, the above studies suggest that further work should
be taken on to rule out or compensate for possible Treg elevation
and inadvertent negation of potentially beneficial anti-tumor
actions that TH17 cells may have in some established tumors.
Figure2. HIF-1 contributes to the production of IL-17 and in the tumor microenvironment may promote cancer progression through multiple
mechanisms. In the tumor microenvironment, Tregs and TH17 cells accumulate. The former population suppresses the action of T effector cells capable
of cancer cell eradication (TH1, CTL) while the exact role of the latter is the subject of some debate. Recent findings suggest that despite a strong
reputation as a pro-inflammatory subset, TH17 cells by virtue of the angiogenesis-promoting effect of their signature cytokines, may promote tumor
development. In the hypoxic tumor microenvironment, Foxp3
+ Tregs can be induced to produce IL-17 as well. It is probable that HIF-1, induced by
hypoxia or the cytokine milieu of the tumor microenvironment is central for the elevation of angiogenesis-promoting cytokines. In addition to this
potential contribution to tumor progression HIF-1 has well documented roles in cancer cell metabolism and other processes as well. HIF-1 targeting
should therefore be explored as a cancer strategy with the potential for sabotaging tumor promoting processes at multiple levels.
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